June 1 (Reuters) - Fulcrum Therapeutics said on Monday it would stop developing its experimental sickle-cell disease drug after the U.S. Food and Drug Administration raised cancer-risk concerns, which ...
June 2 (Reuters) - Shares of Fulcrum Therapeutics plunged 50% in premarket trading on Tuesday after the company said it would ...
Please provide your email address to receive an email when new articles are posted on . In this video, Ronak Mistry, DO, discusses the results of a study presented at ASH Annual Meeting that examined ...
SAN DIEGO -- Treatment with hydroxyurea led to more hematologic dose-limiting toxicities (DLTs) compared with placebo in patients with hemoglobin SC, a milder form of sickle cell disease (SCD), a ...
Sickle cell disease (SCD) is a group of painful and life-threatening genetic disorders that affect hemoglobin, the major protein that carries oxygen in red blood cells. It occurs in nearly 100,000 ...
AND017 is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor. The Food and Drug Administration has granted Orphan Drug designation to KIND Pharmaceutical’s AND017 for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results